2289 (2289) Fair Value & Analysis

Healthcare · Market cap HK$788M

2 2289 2289 · HK

PriceHK$7.30

Fair ValueHK$8.41

Upside+15.2%

Quality52/100

Watch 2289 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$6.31 – HK$10.73

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price +33.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$5.11 – HK$12.65 · fair‑value band HK$6.31 – HK$10.73 · the HK$7.30 price screens below the HK$8.41 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2289 (2289) currently trades at HK$7.30, while our model-based Fair Value estimate is HK$8.41 — implying the stock looks roughly 15.2% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2289 generated revenue of HK$4.4B at a net margin of 1.1%. Revenue grew 6.8% year over year. It earns a return on equity of 7.5%. Net debt stands at HK$1.3B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$4.4B

Revenue growth (YoY) +6.8%

Net margin 1.1%

Return on equity 7.5%

Free cash flow HK$263M FY2025

P/E ratio 14.9

More key figures

Operating margin 2.8%

EPS (TTM) HK$0.2000

Dividend yield 4.4%

EPS growth (YoY) -7.5%

Net debt HK$1.3B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2289 reported revenue of HK$4.4B in FY2025 versus HK$3.8B in FY2021, a compound +3.7%/yr. Reported net income was HK$46.3M in FY2025, compounding +18.9%/yr from FY2021.

Revenue +3.7%/yr

FY21 HK$3.8B

FY22 HK$4.2B

FY23 HK$4.4B

FY24 HK$4.4B

FY25 HK$4.4B

Net income +18.9%/yr

FY21 HK$23.2M

FY22 HK$90.5M

FY23 HK$51.3M

FY24 HK$53.3M

FY25 HK$46.3M

Is 2289 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$999.49	R$1,236	+24%
Cencora, Inc C1CO34	R$707.04	R$79.88	-89%
Cardinal Health, Inc CAH	$201.74	$92.07	-54%
Sigma Healthcare Limited SIGGF	$2.35	$0.6300	-73%
SIG SIG	A$2.92	A$1.20	-59%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥45.15	+183%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2289 (2289) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$8.41 versus a price of HK$7.30 — about +15% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2289?

Our model-based fair value for 2289 is HK$8.41 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$7.30.

What is the quality score of 2289?

2289 has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2289 (2289)?

2289 reported trailing-twelve-month revenue of about HK$4.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2289?

The net profit margin of 2289 is about 1.1%, meaning it keeps roughly 1.1% of revenue as net income. Based on the latest reported figures.

Does 2289 pay a dividend?

2289 currently shows a dividend yield of about 4.44% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.